ArriVent BioPharma, Inc. (AVBP) Stock Forecast
AVBP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 11 analysts
- Price target
- $21.56 average of analyst targets
- Upside to target
- +29.4% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-1.06
- 52-week range
- $15.09 – $34.74
AVBP analyst ratings
11 analystsNumber of analysts at each rating.
AVBP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AVBP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.08 | −$1.22 | −$1.00 | −$0.83 | −29.8% | 10 |
| Current fiscal year (FY2026) | −$4.22 | −$4.94 | −$3.90 | −$4.32 | +2.2% | 11 |
| Next fiscal year (FY2027) | −$3.86 | −$4.80 | −$3.10 | −$4.22 | +8.6% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AVBP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (FY2027) | $7.3M | $0 | $61.0M | 0.0% | 10 |
AVBP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AVBP revenue: reported and forecast
AVBP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.97 | −$1.07 | −$1.07 | −$1.08 | −$1.08 | +11.4% | 2 up · 1 down |
| Current fiscal year (FY2026) | −$4.02 | −$4.34 | −$4.34 | −$4.22 | −$4.22 | +4.9% | 3 up · 0 down |
| Next fiscal year (FY2027) | −$3.50 | −$3.81 | −$3.81 | −$3.87 | −$3.86 | +10.3% | 2 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AVBP earnings surprises
Reported EPS vs the consensus estimate for the last 11 quarters; AVBP beat in 4 of 11.
What analysts expect from AVBP
11 analysts cover ArriVent BioPharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.56, 29.4% above the latest close of $16.66. Analysts expect earnings of −$4.22 per share for FY2026, +2.2% from a year earlier. For FY2027 the average estimate is −$3.86 per share on revenue of $7.3 million. ArriVent BioPharma beat the EPS estimate in 4 of the last 11 quarters.
Related: AVBP income statement, AVBP key metrics, AVBP chart. See the AVBP stock overview for the latest quote and news.
AVBP forecast FAQ
What is ArriVent BioPharma's price target?
The average analyst price target for ArriVent BioPharma is $21.56, 29.4% above the latest close of $16.66.
Is ArriVent BioPharma a buy, hold or sell?
Of 11 analysts covering ArriVent BioPharma, 11 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ArriVent BioPharma's EPS forecast?
Analysts forecast −$4.22 per share for FY2026 (range −$4.94 to −$3.90); for FY2027 the estimate is −$3.86.
When does ArriVent BioPharma report earnings?
ArriVent BioPharma is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-1.06.
Does ArriVent BioPharma usually beat earnings estimates?
ArriVent BioPharma reported EPS at or above the analyst estimate in 4 of the last 11 quarters.